Oligodendroglial and neuronal component in glioblasfomas: Possible relation with prognosis;Componente oligodendroglial e neuronal em glioblastomas: Possível relação com o prognóstico

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 4, 2004, Pages 1074-1078

  Wernersbach Pinto, Luciana ^a,b   Chimelli, Leila ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CNPq   (Brazil)

Author keywords

Glioblastomas; Glioneuronal tumors; Oligodendroglial component; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OLIGODENDROGLIA; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 10944222114     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2004000600026     Document Type: Article

References (20)

1. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In Kleihues P, Cavenee WK (eds). Pathology and genetics: tumours of the nervous system. Lyon: IARC Press, 2000;29-39.
2. Burger PC, Green SB. Patient age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-1625.
3. Burger P, Vollmer RT. Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 1980;46:1179-1186.
4. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225.
5. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomes: classifications de l'OMS et de l'Hôpital Sainte Anne. Ann Pathol 2000;20:413-428.
6. Wolf KH, Buslei R, Blümcke I, Wiestler OD, Pietsch T. Neural antigens in oligodendrogliomas and dysembrioplastic neuroepithelial tumors. Acta Neuropathol 1997;94:436-443.
7. Wharton SB, Chan KK, Hamilton FA, Anderson JR. Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol 1998;24:302-308.
8. Kraus JA, Lamszus K, Glesmann N, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001;101:311-320.
9. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001;60:863-871.
10. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-990.
11. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Perl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-1393.
12. th International Congress of Neuropathology. Torino-Lingotto, September 14-18:145.
13. Azzarelli B, Miravalle L, Vidal R. Immunolocalization of oligodendrocyte transcription factor 1 (Olig1) in brain tumors. J Neuropathol Exp Neurol 2004;63:170-179.
14. Hirato J, Nakazato Y, Ogawa A. Expression of non-glial intermediate filament proteins in gliomas. Clin Neuropathol 1994;13:1-11.
15. Franke FE, Schachenmayr W, Osborn M, Altmannsberger M. Unexpected immunoreactivities of intermediate filament antibodies in human brain and brain tumors. Am J Pathol 1991;139:67-79.
16. Cosgrove M, Fitzgibbons PL, Sherrod A, Chandrasoma PT, Martin SE. Intermediate filament expression in astrocytic neoplasms. Am J Surg Pathol 1989;13:141-145.
17. Giannini C, Scheithauer BW, Lopes MBS, Hirose T, Kros JM, Vandenberg SR. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 2002;26:479-485.
18. Martinez-Diaz H, Kleinschmidt-Demasters BK, Powell SZ, Yachinis A. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but shares reactivity for class III β-tubulin. Arch Pathol Lab Med 2003; 127:1187-1191.
19. Weir B. The relative significance of factors affecting postoperative survival in astrocytomas, grades 3 and 4. J Neurosurg 1973;38:448-452.
20. Boiardi A, Silvani A, Pozzi M, Farinotti L, Fariselli GB, Salmaggi A. Advantage of treating anaplastic gliomas with agressive protocol combining chemotherapy and radiotherapy. J Neuro-Oncol 1997;34:179-185.